Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.56 |
| ▸ | PDE4A | P27815 | 4/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.45 |
| ▸ | TUBB | P07437 | 1/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425323 | 0.86 | RELA (0.54) | RELANFE2L2CYP19A1NQO2CYP1A1 | |
| SCHEMBL26425560 | 0.84 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL26425447 | 0.83 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DRELA | |
| SCHEMBL26425304 | 0.82 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL500087 | 0.80 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL5583429 | 0.80 | PDE4B (0.82) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL26425445 | 0.80 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DRELA | |
| SCHEMBL26425440 | 0.80 | CA1 (0.63) | PDE4BPDE4APDE4CPDE4DRELA | |
| SCHEMBL26425459 | 0.78 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4DNFE2L2 | |
| SCHEMBL26425450 | 0.77 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| EP-4132657-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | The George Washington University (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-111333672-B | Sterol regulatory element binding protein and acidic nucleoplasm DNA binding protein-1 inhibitor, and preparation method and application thereof | 中国医学科学院放射医学研究所 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | TP53, ANXA5, MCL1 | PDE4B 2973/4885PDE4A 3402/4885PDE4C 2702/4885 |
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | PDE4B 2973/4885PDE4A 3402/4885PDE4C 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.